<DOC>
	<DOCNO>NCT02728492</DOCNO>
	<brief_summary>Quisinostat besides efficacy , potentially lead good result polychemotherapy increase mean time progression , may demonstrate Quisinostat lead sustain tumor sensitivity platinum drug . In study safety tolerability multiple administration Quisinostat dos range 8 mg 12 mg combine standard backbone chemotherapy patient non-small cell lung cancer ( second line ) ovarian cancer ( second subsequent line ) investigate .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Quisinostat , Histone Deacetylase Inhibitor , Combination With Chemotherapy</brief_title>
	<detailed_description>It proven Quisinostat increase HDAC1-inhibited E-cadherin expression ( low concentration 30 nM ) increase susceptibility epidermal growth factor inhibitor case non-small-cell lung cancer stop proliferation paclitaxel-resistant cell . Thus , besides efficacy , potentially lead good result polychemotherapy increase mean time progression , may demonstrate Quisinostat lead sustain tumor sensitivity platinum drug possibly resensitiztion case acquire primary resistance . The main objective study evaluate safety tolerability Quisinostat multiple ascend dos establish maximum tolerate dose ( MTD ) , administer combination standard backbone chemotherapy , follow : Gemcitabine + Cisplatin patient non-small-cell lung cancer ( second line ) Paclitaxel + Carboplatin patient non-small-cell lung cancer ( second line ) patient ovarian cancer ( second subsequent line ) . MTD define maximum dose DLT occur 1 patient 6 . Secondary objective : • Study pharmacokinetics ( PK ) multiple dose Quisinostat administer combination chemotherapy , follow : Gemcitabine + Cisplatin patient non-small-cell lung cancer ( second line ) Paclitaxel + Carboplatin patient non-small-cell lung cancer ( second line ) patient ovarian cancer ( second subsequent line ) Preliminary estimation possible effect drug , add chemotherapy , tumor growth .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>General criterion inclusion patient nonsmall cell lung cancer ( NSCLC ) ovarian cancer ( OC ) : 1 . Signed patient 's information sheet informed consent form participate study 2 . Age 18 old 3 . The value leave ventricular ejection fraction , determine echocardiography data , 50 % 4 . Patient 's ability carry visit study procedure comply protocol 5 . Requirements laboratory parameter determine : Complete blood count : Absolute neutrophil count : Platelets : Haemoglobin : ≥ 1500/mm3 ( 1.5 x 109 cells/l ) 100 000/mm3 ( 100 x 109 cells/l ) 9.0 g/dl Liver function : Total bilirubin : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) : ≤ 1.5fold upper limit normal ( ULN ) ≤ 2.5fold ULN ≤ 5.0fold ULN case metastases liver Kidney function : GRF ( CockcroftGault equation ) &gt; 50 ml/min 6 . The expected survival time le 6 month 7 . Women men childbearing potential ( sterile menopause le 2 year ) must practice effective method birth control start screening period , study 6 month last administration investigational product . Effective method include use condom diaphragm ( barrier method ) spermicide . 8 . Functional status patient accord ECOG 0 2 Special criterion patient NSCLC 9 . Histologically cytologically confirm diagnosis nonresectable nonsmallcell lung cancer 10 . The progression lung cancer maximum one line systemic anticancer therapy ( adjuvant chemotherapy consider firstline therapy time moment completion disease progression le 6 month ) 11 . No history treatment Gemcitabine patient plan inclusion group chemotherapy Cisplatin Gemcitabine , Paclitaxel patient plan inclusion group Carboplatin Paclitaxel . 12 . Vital capacity lung spirometry data 50 % normal screen Special inclusion criterion patient ovarian cancer 13 . Histologically confirm diagnosis ovarian cancer . 14 . Progression three mode anticancer drug therapy ovarian cancer . 1 . Indications Xray therapy chemoradiation therapy time inclusion , regardless treated area ; 2 . Presence clinical and/or radiological sign metastasis brain meningeal structure ( CNS ) ; 3 . Previous therapy HDAC inhibitor 4 . Any contraindication chemotherapy Gemcitabine + Cisplatin Paclitaxel + Carboplatin ( patient lung cancer ) ; contraindication chemotherapy accord standard chemotherapy combination scheme Paclitaxel + Carboplatin ( female patient ovarian cancer ) ; 5 . Any contraindication administration glucocorticosteroids , antihistamine drug , serotonin 5HT3 receptor antagonist , aprepitant ; 6 . Any contraindication force rehydration and/or administration force diuresis ( case lung cancer ) ; 7 . Conditions require continuous use oral anticoagulant , clinically significant change blood coagulation parameter screen ( INR &gt; 1.5 , aPTT &gt; 1.5 х ULN ) 8 . Conditions require admission prohibit drug , impossibility replace allow drug study 9 . Current infection systemic condition constitute contraindication intend chemotherapy ; 10 . Diseases digestive system may infringe absorption investigational product ( Crohn 's disease , nonspecific ulcerative colitis , irritable bowel syndrome ) 11 . Clinically significant cardiovascular disease include : Myocardial infarction within 12 month screen Unstable angina within 12 month screen Congestive heart failure Class III IV accord New York Heart Association criterion ( NYHA ) Clinically significant ventricular arrhythmia include ventricular tachycardia , ventricular fibrillation , history cardiac arrest , atrioventricular block ( Mobitz II III ) , use cardiostimulator QTc interval &gt; 450 m men 470 m woman ( ECG ) ( calculate accord Fredericia formula ) , diagnosis long QT syndrome Hypotension ( systolic blood pressure &lt; 86 mm Hg bradycardia heart rate &lt; 50 beat per minute ( ECG ) except cause medication ( e.g . betablockers ) . Uncontrolled arterial hypertension ( systolic arterial pressure &gt; 170 millimeter mercury diastolic blood pressure &gt; 105 millimeter mercury ) 12 . Pregnancy lactation 13 . Presence HIV antibody , Hepatitis В С antibodies 14 . Drug alcohol abuse moment screen past accord opinion Investigator make patient unsuitable participation study 15 . Significant allergic reaction medical history 16 . Participation clinical study administration test drug 30 day begin study persist side effect test drug ; 17 . Toxic effect previous treatment complication surgical treatment resolve grade 1 and/or 0 ( accord CTCAE scale ) . 18 . Patient willing participate study unable understand follow protocol instruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>